Monopar Therapeutics Inc. Reports Q2 2025 Net Loss of $2.5 Million, EPS of $0.35, Up from Q2 2024's $1.7 Million Loss and $0.49 EPS
Monopar Therapeutics Inc. reported a Q2 2025 net loss of $2.5 million, an increase from a $1.7 million loss in Q2 2024. EPS for Q2 2025 was $0.35, up from $0.49 in the previous year. R&D expenses rose to $1.73 million, driven by higher personnel costs. The company holds $53.3 million in cash and investments, expected to fund operations until December 2026. Monopar is advancing its drug pipeline, including plans for a New Drug Application for ALXN1840 in early 2026 and ongoing clinical trials for MNPR-101.
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, announced its financial results for the second quarter ended June 30, 2025. The company reported a net loss of $2.5 million for the second quarter of 2025, compared to a net loss of $1.7 million for the same period in 2024. Research and Development expenses increased to $1.73 million in the second quarter of 2025 from $1.13 million in the second quarter of 2024, primarily due to a $636,300 rise in R&D personnel expenses, including stock-based compensation. Monopar’s cash, cash equivalents, and investments as of June 30, 2025, totaled $53.3 million, which is expected to support operations through December 31, 2026. Monopar is actively advancing its pipeline, having recently taken over sponsorship of the IND application for ALXN1840 for Wilson Disease from Alexion Pharmaceuticals, with plans to submit a New Drug Application to the FDA in early 2026. The company is also progressing with its MNPR-101-Zr and MNPR-101-Lu Phase 1 clinical trials in advanced cancers in Australia and the U.S., and continuing its preclinical work on MNPR-101-Ac. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Monopar Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001437749-25-026043), on August 12, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT) Original Document: here
